Digistain Study in Solid Tumours

• Research type

  Research Study

• Full title

  Evaluation of biomarkers for better risk stratification in solid tumours using spectroscopy

• IRAS ID

  329294

• Contact name

  Manveer Sroya

• Contact email

  manveer@digistain.co.uk

• Sponsor organisation

  Digistain LTD

• Duration of Study in the UK

  1 years, 0 months, 0 days

• Research summary

  In this study we will use a Fourier-Transform (FT-IR) Spectroscopy method to examine the chemical biomarkers of the tumour which can be related to the severity of the cancer.
  The cancer types that we will look at are breast, renal cell carcinoma, urothelial cancer, colorectal and prostate cancer. These are the cancer types where the current methods of risk stratification are inadequate, expensive or unavailable.

  The spectroscopy based test will be conducted on the left over surgical tumour sample.
  The test will be validated, by comparing with patients who had an early relapse, and assessing the difference in relapsed vs non relapsed cohort.

  The purpose of this study is to evaluate chemical biomarkers that can be used for risk stratification and guide clinical decision making for solid tumours. If risk of recurrence can be predicted using this method, it will mean that many patients will be spared aggressive adjuvant therapy.

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  23/PR/1129

• Date of REC Opinion

  23 Oct 2023

• REC opinion

  Further Information Favourable Opinion